In addition, early failure within the first 6 months was more common in patients with MetSyn. As a component of MetSyn, diabetes mellitus increases the risk of lower extremity peripheral arterial disease (PAD) by 2- to 4-fold and is present in 12?20% of individuals with lower extremity PAD.16-20 In the Framingham Heart Study, diabetes increased the risk of intermittent claudication by 3.5- and 8.6-fold in men and women, respectively.21 The risk of developing Inhibitors,research,lifescience,medical lower extremity PAD is proportional to the severity and duration of diabetes.22,23 The risk of developing CLI is also greater in diabetics than nondiabetics.24, 25 Diabetic patients with lower extremity

PAD are 7- to 15-fold more likely to undergo a major amputation than nondiabetics with lower extremity PAD.25-27 Lida and colleagues reported treatment outcomes after endovascular therapy on 465 limbs with CLI and isolated below-the-knee lesions. They identified diabetes as one of the factors associated Inhibitors,research,lifescience,medical with major amputation.28 Zhan

and associates compared early and Selleck Caspase inhibitor initial hemodynamic outcomes of endovascular therapy and open revascularization in 85 consecutive patients with diabetes and CLI who underwent 109 interventions collectively. There was a similar significant initial hemodynamic improvement between the two interventions.29 Inhibitors,research,lifescience,medical This suggests that the inferior intermediate or long-term results seen in diabetic patients is not necessarily due to the initial hemodynamic response but more likely due to the effects of diabetes on plaque characteristics Inhibitors,research,lifescience,medical and cardiovascular health and the durability of the intervention in such patients. In a study by Ryu and colleagues comparing clinical outcomes between diabetic and nondiabetic patients with CLI who underwent infrapopliteal angioplasty, diabetic patients had an unfavorable primary patency at 2 years compared

to nondiabetic patients.30 However, there was no significant difference between the two groups in terms of limb salvage and survival. Inhibitors,research,lifescience,medical The authors noted that the main obstacles to recanalization or long-term patency include long, multiple, and calcified stenosis or small-diameter vessels that have a tendency towards restenosis.30 Impact of TASC Classification on Performance of PTA Primary patency is influenced tuclazepam by the extent of disease.31 The TASC classification for infrapopliteal lesions offers standardized criteria to define lesion characteristics. A single stenosis <1 cm long is classified as TASC A. TASC B includes multiple focal stenosis <1 cm long or 1-2 stenoses <1 cm involving the trifurcation. TASC C lesion characteristics include a stenosis 1-4 cm long, occlusion 1-2 cm long, or extensive stenosis involving the trifurcation. An occlusion >2 cm long or diffusely diseased arteries are considered TASC D lesions.